Product Information
NAYZILAM 5 MG NASAL SPRAY is a brand product labeled by UCB, Inc., priced at $327.0477 per EA under NDC 50474050015. Its NADAC has been published 342 times since Mar 18, 2020.
FDA first approved this application on May 17, 2019.
The High Outlier badge above means this manufacturer's average price in the midazolam market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
5 mg/.1mL
Manufacturer
UCB, Inc.NDC
50474050015
Classification
Brand
Dosage Form
SPRAY
Route
NASAL
Effective Date
9/23/2026
Active Ingredients
MIDAZOLAMApproval Type
New Drug (NDA)
FDA Application
NDA211321FDA Approved
5/17/2019
On Market Since
5/17/2019
Pharmacological Classes
Price Statistics
The NADAC for NAYZILAM 5 MG NASAL SPRAY has been published 342 times since Mar 18, 2020, and over the history we have for it it has risen 23.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $327.0477 per EA |
|---|---|
| All-time high | $327.6376 (May 13, 2026) |
| All-time low | $263.8393 (Jan 20, 2021) |
| 52-week high | $327.6376 |
| 52-week low | $319.2792 |
| Median price | $299.4883 |
| Average price | $295.1421 |
| Largest weekly change | +6.9% (Jan 12, 2022) |
| Weeks tracked | 342 |
| Tracking since | Mar 18, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the midazolam market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
UCB, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
midazolam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NAYZILAM 5 MG NASAL SPRAY?
The current National Average Drug Acquisition Cost (NADAC) for NAYZILAM 5 MG NASAL SPRAY, manufactured by UCB, Inc., is $327.0477 per EA (NDC 50474050015), effective Sep 30, 2026.
How has the price of NAYZILAM 5 MG NASAL SPRAY changed over time?
Over the history we have for it, the NADAC for NAYZILAM 5 MG NASAL SPRAY has risen 23.9%. It has been tracked across 342 weekly CMS publications since Mar 18, 2020.
What are the highest and lowest recorded NADAC prices for NAYZILAM 5 MG NASAL SPRAY?
Since Mar 18, 2020, the NADAC for NAYZILAM 5 MG NASAL SPRAY has ranged from a low of $263.8393 (Jan 20, 2021) to a high of $327.6376 (May 13, 2026), with a median of $299.4883 per EA.
Are there cheaper alternatives to NAYZILAM 5 MG NASAL SPRAY?
No other NADAC-published product currently shares the active ingredient and strength of NAYZILAM 5 MG NASAL SPRAY in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NAYZILAM 5 MG NASAL SPRAY?
NAYZILAM 5 MG NASAL SPRAY (NDC 50474050015) is labeled by UCB, Inc., and CMS classifies it as a brand product.